Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake ...

Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA study.

As a result of comparing patients with minimally invasive surgery and laparotomy during endometrial cancer surgery, it was ...

Data suggest that adding an ARPI to standard care improves outcomes for most patients with mHSPC, but those benefits decrease with age.

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...